Loading stock data…
Cartesian Therapeutics (RNAC)
$7.88-0.04 (-0.51%)
Market ClosedLast close Jul 24
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cartesian Therapeutics, Inc. in the Healthcare sector is trading at $7.88 with a market capitalization of $255M. Wall Street consensus targets $34.57 (7 analysts), implying a +338.7% move over the next 12 months. The stock is currently 46% below its 52-week high of $14.56, remaining 3.4% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 9 is oversold, raising the odds of a near-term bounce. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +338.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 9) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $78,000↓ | $947,000↑ | $452,000↑ | $298,000↓ | $1.10M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$26.50M↓ | -$21.94M↓ | -$21.07M↑ | -$21.81M↑ | -$21.89M |
| Net Income | -$39.18M↑ | -$92.58M↓ | -$35.90M↓ | $15.89M↑ | -$17.71M |
Peer Comparison
JNJUNHPFE
Fundamentals
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cel...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$254.59M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
102.47%
Volume
Today's trading volume
143,286
Recent News
Kyverna Therapeutics Sinks 13%: Here’s Why
A single analyst note sent Kyverna Therapeutics tumbling despite a clinical milestone that had investors cheering just weeks ago, and the question now is whether the selloff marks a buying opportunity or the start of a painful unwind.
New Strong Sell Stocks for July 1st
CZR, RNAC and NSP have been added to the Zacks Rank #5 (Strong Sell) List on July 1, 2026.
Kiniksa Pharmaceuticals International, plc (KNSA) Surges 5.4%: Is This an Indication of Further Gains?
Kiniksa Pharmaceuticals International, plc (KNSA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine
Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted its ‘in vivo’ cell therapy capabilities.
FDA Clears Imviva’s Dual-Target CAR-T for Autoimmune Diseases
By Karen Roman Imviva Biotech said the FDA cleared its Investigational New Drug application for CTA313, a dual-targeted CAR-T therapy for the treatment of B-cell-mediated autoimmune diseases. Phase 1b of this clinical trial will study CTA313 in patients with systemic lupus erythematosus, progressive multiple sclerosis, and autoimmune encephalitis, among other autoimmune conditions, the company stated. […] The post FDA Clears Imviva’s Dual-Target CAR-T for Autoimmune Diseases appeared first on Ex